Hamilton Lane Advisors LLC Purchases New Position in Natera, Inc. (NASDAQ:NTRA)

Hamilton Lane Advisors LLC purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 9,833 shares of the medical research company's stock, valued at approximately $616,000. Natera makes up about 0.3% of Hamilton Lane Advisors LLC's portfolio, making the stock its 20th biggest holding.

A number of other hedge funds have also recently made changes to their positions in NTRA. Allspring Global Investments Holdings LLC grew its position in Natera by 28.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 720,160 shares of the medical research company's stock worth $45,111,000 after acquiring an additional 159,993 shares during the last quarter. Cerity Partners LLC increased its stake in shares of Natera by 1,043.3% in the fourth quarter. Cerity Partners LLC now owns 90,423 shares of the medical research company's stock worth $5,664,000 after buying an additional 82,514 shares during the period. WCM Investment Management LLC raised its holdings in Natera by 101.2% during the 4th quarter. WCM Investment Management LLC now owns 145,996 shares of the medical research company's stock valued at $9,058,000 after buying an additional 73,419 shares during the last quarter. abrdn plc purchased a new stake in Natera during the 4th quarter valued at $3,214,000. Finally, Aigen Investment Management LP bought a new stake in Natera in the 3rd quarter worth $223,000. 99.90% of the stock is currently owned by institutional investors.

Natera Stock Up 10.2 %

NASDAQ NTRA traded up $9.74 during trading hours on Friday, reaching $105.29. 3,499,347 shares of the company's stock traded hands, compared to its average volume of 1,180,271. The firm has a market cap of $12.71 billion, a PE ratio of -33.75 and a beta of 1.38. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.10 and a quick ratio of 3.96. Natera, Inc. has a 52-week low of $36.90 and a 52-week high of $108.32. The firm has a 50-day simple moving average of $92.32 and a 200 day simple moving average of $71.70.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.56) EPS for the quarter, topping analysts' consensus estimates of ($0.72) by $0.16. Natera had a negative return on equity of 51.09% and a negative net margin of 30.24%. The firm had revenue of $367.70 million for the quarter, compared to analysts' expectations of $316.31 million. During the same period in the previous year, the firm posted ($1.23) EPS. The business's revenue for the quarter was up 52.1% compared to the same quarter last year. Sell-side analysts anticipate that Natera, Inc. will post -2.35 EPS for the current fiscal year.

Insider Activity

In related news, Director Herm Rosenman sold 93,901 shares of the company's stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $69.37, for a total value of $6,513,912.37. Following the transaction, the director now owns 61,685 shares in the company, valued at approximately $4,279,088.45. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Natera news, insider Jonathan Sheena sold 447 shares of the business's stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $90.22, for a total value of $40,328.34. Following the completion of the transaction, the insider now owns 347,731 shares of the company's stock, valued at approximately $31,372,290.82. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Herm Rosenman sold 93,901 shares of the company's stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $69.37, for a total transaction of $6,513,912.37. Following the transaction, the director now owns 61,685 shares in the company, valued at approximately $4,279,088.45. The disclosure for this sale can be found here. Insiders sold 410,750 shares of company stock worth $35,002,520 over the last three months. 7.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

NTRA has been the subject of several recent analyst reports. StockNews.com downgraded shares of Natera from a "hold" rating to a "sell" rating in a research note on Thursday. The Goldman Sachs Group increased their price objective on Natera from $90.00 to $100.00 and gave the stock a "buy" rating in a report on Monday, April 15th. Sanford C. Bernstein upgraded Natera from a "market perform" rating to an "outperform" rating and set a $120.00 price objective on the stock in a research report on Friday, April 5th. TD Cowen upped their target price on Natera from $123.00 to $137.00 and gave the company a "buy" rating in a report on Friday. Finally, Canaccord Genuity Group lifted their price target on shares of Natera from $100.00 to $130.00 and gave the company a "buy" rating in a report on Friday. One research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $95.13.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.